A sulphonoglycolipid from the fern Polypodium decumanum and its effect on the platelet activating-factor receptor in human neutrophils

Journal of Pharmacy and Pharmacology

Volumn 49, Issue 5, 1997, Pages 562-566

  Vasänge, Mervi ^a   Rolfsen, Wenche ^a   Bohlin, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALAGUALA; GLYCOLIPID; PLANT EXTRACT; POLYPODIUM DECUMANUM; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXOCYTOSIS; FERN; HUMAN; HUMAN CELL; NEUTROPHIL; NORMAL HUMAN; PATHOGENESIS; PSORIASIS; SPECTROSCOPY;

EID: 0030980733     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1997.tb06842.x     Document Type: Article

References (27)

1. Amarquaye, A., Che, C., Bejar, E., Malone, M., Fong, H. H. (1994) A new glycolipid from Byrsonima crassifolia. Planta Med. 60: 85-86
2. Benning, C., Beatty, J. T., Prince, R. C., Somerville, C. R. (1993) The sulfolipid sulfoquinivosyldiacylglycerol is not required for photosynthetic electron transport in Rhodobacter sphaeroides but enhances growth under phosphate limitation. Proc. Natl Acad. Sci. 90: 1561-1565
3. Braquet, P. (1987) The ginkgolides. Potent platelet-activating factor antagonists isolated from Ginkgo biloba: chemistry, pharmacology and clinical applications. Drugs Fut. 12: 643-699
4. Braquet, P., Esanu, A. (1991) New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. Agents Actions 32: 34-36
5. Braquet, P., Touqui, L., Shen, T. Y., Vargaftig, B. B. (1987) Perspectives in platelet activating factor research. Pharm. Rev. 39: 97-145
6. Chao, W., Ohlson, M. S. (1993) Platelet activating factor; receptors and signal transduction. Biochem. J. 292: 617-629
7. Clay, K. L., Johnson, C., Henson, P. (1990) Binding of platelet activating factor to albumin. Biochim. Biophys. Acta 1046: 309-314
8. Cunningham, F. (1990) Lipid mediators in inflammatory skin disorders. J. Lipid Med. 2: 61-74
9. Del Pino Gamboa, J., De Sambricio Guiu, I., Colomo Gomez, C. (1982) Comparative study between 120 mg anapsos and a placebo in 37 psoriasis patients. Med. Cutan Ibero Lat. Am. 10: 203-208
10. Dewald, B., Baggiolini, M. (1987) Evaluation of PAF antagonists using human neutrophils in a microtiter plate assay. Biochem. Pharmacol. 36: 2505-2510
11. Gustafson, K. R., Cardellina, J. H., Fuller, R. W., Weislow, O. S., Kiser, R. F. (1989) AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae) J. Natl Cancer Inst. 81: 1254-1258
12. Jimenez, D., Doblare, E., Naranjo, R., Munoz, C., Vargas, J. F. (1987) Anapsos, an anti-psoriatic drug, in atopic dermatitis. Allergol. Immunopathol. 15: 185-189
13. Koltai, M., Hosford, D., Esanu, A., Braquet, P. (1991a) Recent progress in PAF antagonist research. In: Braquet, P. (ed.) Handbook of PAF Antagonists. CRC Press, Boca Raton, Florida, pp 3-70
14. Koltai, M., Hosford, D., Guinot, P., Esanu, A., Braquet, P. (1991b) Platelet activating factor. A review of its effects, antagonists and possible future clinical implications. Drugs 42: 9-29
15. 3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes. J. Pharmacol. Exp. Ther. 244: 709-715
16. Marquis, O., Robaut, C., Cavero, I. (1989) Evidence for the existence and ionic modulation of platelet activating factor receptors mediating degranulatory responses in human polymorphonuclear leukocytes. J. Pharmacol. Exp. Ther. 250: 293-300
17. Mohammad, A. (1989) Vitiligo repigmentation with anapsos (Polypodium leucotomos). Int. J. Derm. 28: 479
18. Morimoto, T., Murakami, N., Nagatsu, A., Sakakibara, J. (1993) Studies on glycolipids VII. Isolation of two new sulfoquinovosyl diacylglycerols from the green alga Chlorella vulgaris. Chem. Pharm. Bull. 41: 1545-1548
19. O'Flaherty, J. T., Suries, J. R., Redman, J., Jacobson, D., Piantadosi, C., Wykle, R. (1986) Binding and metabolism of platelet activating factor by human neutrophils. J. Clin. Invest. 78: 381-388
20. Padilla, H. C., Lainez, N. H., Pacheco, J. A. (1974) New agent (hydrophilic fraction of Polypodium leucotomos) for management of psoriasis. Int. J. Dermatol. 13: 276-282
21. Sawyer, D. B., Andersen, O. S. (1989) Platelet activating factor is a general membrane perturbant. Biochim. Biophys. Acta 987: 129-132
22. Seppänen-Laakso, T., Laakso, I., Hiltunen, R. (1990) Simultaneous analysis of bound and free fatty acids in human plasma by quantitative gas chromatography. Acta Pharm. Fenn. 99: 109-117
23. Shirahashi, H., Murakami, N., Watanabe, M., Nagatsu, A., Sakakibara, J., Tokuda, H., Nishino, H., Iwashima, A. (1993) Isolation and identification of anti-tumor-promoting principles from the freshwater cyanobacterium Phormidium tenue. Chem. Pharm. Bull. 41: 1664-1666
24. Tuominen, M., Lindbom, L.-I., Bohlin, L., Rolfsen, W. (1991) Enhancing effect of calaguala on the prevention of rejection on skin transplants in mice. Phytother. Res. 5: 234-236
25. Tuominen, M., Bohlin, L., Rolfsen, W. (1992) Effects of calaguala and an active principle, adenosine, on platelet activating factor. Planta Med. 58: 306-310
26. Vargas Gonzales, J. F., Lopez Gutierrez, M. (1988) Anapsos, a new therapeutic approach in the digestive pathology of atopic dermatitis patients. Acta Pediatric. Esp. 46: 556-561
27. Vasänge-Tuominen, M., Perera-Ivarsson, P., Shen, J., Bohlin, L., Rolfsen, W. (1994) The fern Polypodium decumanum, used in the treatment of psoriasis, and its fatty acid constituents, as inhibitors of leukotriene B4 formation. Prostaglandin Leukot. Essent. Fatty Acids 50: 279-284